Illumina (ILMN) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Illumina (ILMN) has outperformed Labcorp (LH) over the past year, gaining 170.6% versus a gain of 13.2%. Over five years, LH leads with a +34.7% price change compared with -33.7% for ILMN. Illumina is the larger company by market cap ($42.00 billion vs $25.32 billion), about 1.7 times the size, while Labcorp is growing revenue faster (+7.2% vs -0.7%).
On valuation, Labcorp trades at a lower forward P/E (15.8x vs 45.5x for Illumina). Labcorp pays a dividend yielding 0.92%, while Illumina does not currently pay one. Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 6.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ILMN | LH |
|---|---|---|
| Share price | $278.17 | $312.15 |
| Market cap | $42.00B | $25.32B |
| 1-day change | +5.14% | -0.65% |
| YTD return | +101.72% | +25.24% |
| 1-year return | +170.58% | +13.22% |
| 5-year return | -33.65% | +34.66% |
| P/E ratio (TTM) | 51.90 | 25.82 |
| Forward P/E | 45.46 | 15.78 |
| EPS (TTM) | $5.36 | $12.09 |
| Dividend yield | 0.00% | 0.92% |
| Annual dividend | $0.00 | $2.88 |
| Revenue (latest FY) | $4.34B | $13.95B |
| Revenue growth (YoY) | -0.66% | +7.25% |
| Net income (latest FY) | $850.00M | $876.50M |
| Gross margin | 66.08% | 28.76% |
| Operating margin | 18.58% | 9.92% |
| Net margin | 19.57% | 6.28% |
| 52-week high | $309.35 | $341.80 |
| 52-week low | $88.00 | $244.52 |
| Distance from 52-week high | -10.08% | -8.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -16.54% | +10.26% |
| Average volume | 2.69M | 742.58K |
| Shares outstanding | 151.00M | 81.10M |
| Employees | 8,600 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed LH by 157.4 percentage points over the past year.
- Illumina trades at a higher earnings multiple (51.9x vs 25.8x trailing P/E).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 6.3 cents for Labcorp.
- Labcorp grew revenue faster in its latest fiscal year (+7.25% vs -0.66%).
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
ILMN vs LH FAQ
Which is bigger, Illumina or Labcorp?
Illumina (ILMN) is larger, with a market capitalization of $42.00B compared with $25.32B for Labcorp (LH).
Which stock has performed better over the past year, ILMN or LH?
ILMN returned +170.58% over the past 12 months, compared with +13.22% for LH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ILMN or LH?
LH has the lower trailing P/E at 25.8, versus 51.9 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Illumina or Labcorp?
Labcorp pays a dividend yielding 0.92%, while Illumina does not currently pay a regular dividend.
Are Illumina and Labcorp in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.